Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥79.81 Million ≈ $11.68 Million USD) by net assets (CN¥3.72 Billion ≈ $543.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shandong Jincheng Pharmaceutical and Che total liabilities for a breakdown of total debt and financial obligations.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Group Up Industrial Co Ltd
TWO:6664
|
0.027x |
|
MannKind Corp
NASDAQ:MNKD
|
-0.527x |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
-0.032x |
|
Tangrenshen Group Co Ltd
SHE:002567
|
0.028x |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
0.048x |
|
Aoyuan Beauty Valley Technology Co Ltd
SHE:000615
|
0.035x |
|
Service Stream Ltd
AU:SSM
|
0.101x |
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
N/A |
Annual Cash Flow Conversion Efficiency for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Shandong Jincheng Pharmaceutical and Che.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.83 Billion ≈ $560.76 Million |
CN¥296.59 Million ≈ $43.40 Million |
0.077x | -55.93% |
| 2023-12-31 | CN¥3.78 Billion ≈ $553.29 Million |
CN¥664.08 Million ≈ $97.18 Million |
0.176x | +151.42% |
| 2022-12-31 | CN¥3.66 Billion ≈ $535.47 Million |
CN¥255.63 Million ≈ $37.41 Million |
0.070x | -45.04% |
| 2021-12-31 | CN¥3.44 Billion ≈ $503.30 Million |
CN¥437.19 Million ≈ $63.97 Million |
0.127x | -19.30% |
| 2020-12-31 | CN¥3.47 Billion ≈ $507.37 Million |
CN¥546.13 Million ≈ $79.92 Million |
0.158x | +11.32% |
| 2019-12-31 | CN¥4.08 Billion ≈ $597.74 Million |
CN¥577.98 Million ≈ $84.58 Million |
0.141x | +64.24% |
| 2018-12-31 | CN¥4.09 Billion ≈ $598.21 Million |
CN¥352.20 Million ≈ $51.54 Million |
0.086x | +123.44% |
| 2017-12-31 | CN¥3.94 Billion ≈ $576.20 Million |
CN¥151.83 Million ≈ $22.22 Million |
0.039x | -75.98% |
| 2016-12-31 | CN¥1.50 Billion ≈ $220.11 Million |
CN¥241.48 Million ≈ $35.34 Million |
0.161x | +1.17% |
| 2015-12-31 | CN¥1.31 Billion ≈ $191.74 Million |
CN¥207.92 Million ≈ $30.42 Million |
0.159x | -19.26% |
| 2014-12-31 | CN¥1.12 Billion ≈ $163.40 Million |
CN¥219.46 Million ≈ $32.11 Million |
0.197x | +113.78% |
| 2013-12-31 | CN¥1.02 Billion ≈ $149.51 Million |
CN¥93.92 Million ≈ $13.74 Million |
0.092x | +3.55% |
| 2012-12-31 | CN¥975.57 Million ≈ $142.76 Million |
CN¥86.61 Million ≈ $12.67 Million |
0.089x | +35.78% |
| 2011-12-31 | CN¥958.84 Million ≈ $140.31 Million |
CN¥62.69 Million ≈ $9.17 Million |
0.065x | -77.42% |
| 2010-12-31 | CN¥375.33 Million ≈ $54.92 Million |
CN¥108.67 Million ≈ $15.90 Million |
0.290x | -22.83% |
| 2009-12-31 | CN¥281.53 Million ≈ $41.20 Million |
CN¥105.62 Million ≈ $15.46 Million |
0.375x | +168.69% |
| 2008-12-31 | CN¥216.49 Million ≈ $31.68 Million |
CN¥30.23 Million ≈ $4.42 Million |
0.140x | -- |
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. Shandong Jincheng Pharmaceutical Group Co., Ltd was founded in 2004 and is based in Zibo, China.